INGN 241 in phase II clinical trial

Article

Source: www.biotechnologyhealthcare.com Austin, Texas ? Introgen Therapies announced initiation of a Phase II clinical trial of INGN 241 in patients with metastatic melanoma.

Related Videos
Related Content

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Expert Insights on Rapid Weight Loss, Semaglutide, and Aesthetic Procedures

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

Derm In The News: September 17-23

September 23rd 2023

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Expert Insights on Rapid Weight Loss, Semaglutide, and Aesthetic Procedures

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

Derm In The News: September 17-23

September 23rd 2023

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Expert Insights on Rapid Weight Loss, Semaglutide, and Aesthetic Procedures

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

Derm In The News: September 17-23

September 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.